首页> 外文期刊>Translational psychiatry. >BDNF promoter methylation and genetic variation in late-life depression
【24h】

BDNF promoter methylation and genetic variation in late-life depression

机译:抑郁症中 BDNF 启动子甲基化和遗传变异

获取原文
           

摘要

The regulation of the brain-derived neurotrophic factor (BDNF) is important for depression pathophysiology and epigenetic regulation of the BDNF gene may be involved. This study investigated whether BDNF methylation is a marker of depression. One thousand and twenty-four participants were recruited as part of a longitudinal study of psychiatric disorders in general population elderly (age?65). Clinical levels of depression were assessed using the Mini International Neuropsychiatric Interview for the diagnosis of major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorder IV criteria, and the Centre for Epidemiologic Studies Depression Scale (CES-D) for assessment of moderate to severe depressive symptoms. Buccal DNA methylation at the two most widely studied BDNF promoters, I and IV, was investigated using the Sequenom MassARRAY platform that allows high-throughput investigation of methylation at individual CpG sites within defined genomic regions. In multivariate linear regression analyses adjusted for a range of participant characteristics including antidepressant use, depression at baseline, as well as chronic late-life depression over the 12-year follow-up, were associated with overall higher BDNF methylation levels, with two sites showing significant associations (promoter I, Δ mean=0.4%, P =0.0002; promoter IV, Δ mean=5.4%, P =0.021). Three single-nucleotide polymorphisms ( rs6265 , rs7103411 and rs908867 ) were also found to modify the association between depression and promoter I methylation. As one of the largest epigenetic studies of depression, and the first investigating BDNF methylation in buccal tissue, our findings highlight the potential for buccal BDNF methylation to be a biomarker of depression.
机译:脑源性神经营养因子(BDNF)的调节对于抑郁症的病理生理很重要,可能涉及BDNF基因的表观遗传调节。这项研究调查了BDNF甲基化是否是抑郁症的标志。一项针对一般人群老年人(65岁)的精神疾病纵向研究的一部分,共招募了124名参与者。根据《精神障碍诊断和统计手册》 IV标准,使用Mini International Neuropsychiatric Interview对抑郁症的临床水平进行评估,以诊断重度抑郁症,并通过流行病学研究抑郁量表(CES-D)评估中度至重度严重的抑郁症状。使用Sequenom MassARRAY平台对两个研究最广泛的BDNF启动子I和IV的颊DNA甲基化进行了研究,该平台可对定义的基因组区域内单个CpG位点的甲基化进行高通量研究。在针对一系列参与者特征进行校正的多元线性回归分析中,包括12年随访中的抗抑郁药使用,基线抑郁以及慢性后期抑郁,与总体较高的BDNF甲基化水平相关,其中两个位点显示显着相关(启动子I,Δ均值= 0.4%,P = 0.0002;启动子IV,Δ均值= 5.4%,P = 0.021)。还发现了三个单核苷酸多态性(rs6265,rs7103411和rs908867)来修饰抑郁症和启动子I甲基化之间的关联。作为最大的抑郁症表观遗传学研究之一,也是首次对颊组织中BDNF甲基化进行研究,我们的发现凸显了颊BDNF甲基化成为抑郁症的生物标志物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号